Longeveron LGVN
Longeveron FY 2024: revenue $2.4M, up 237%; diluted EPS −$2.62
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-25-029968
Key figures from this report
These are the numbers Longeveron reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$2.4M+237% from $709K in FY 202310-K income statement, on EDGAR
- Net income−$16.0MAgainst −$21.4M in FY 202310-K income statement, on EDGAR
- Diluted EPS−$2.62Against −$1.02 in FY 202310-K income statement, on EDGAR
- Cash and cash equivalents$19.2M+289% from $4.9M in FY 2023Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$13.9MAgainst −$19.0M in FY 202310-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Lipocine LPCN public float $16M, Jun 30, 2025
- Marker Therapeutics MRKR public float $17M, Jun 30, 2025
- CalciMedica CALC public float $16M, Jun 30, 2025
- Ernexa Therapeutics ERNA public float $18M, Jun 30, 2025
- Charlie's Holdings CHUC public float $18M, Jun 30, 2025
